Moreover, the successful development of I-DXd complements the limitations observed with the only other ADC for cervical cancer, Tisotumab Vedotin, which targets tissue factor (TF) but is associated with significant ocular and peripheral neurotoxicity [56, 57]. This evidence concerns the gene F3 and cervical cancer.